Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Diabetes Care|July 15, 2016
Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose ControlSusanne Famulla, Ulrike Hövelmann, Annelie Fischer, et al.
Diabetes, Obesity & Metabolism|January 26, 2018
Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanismEric Zijlstra, Hans-Veit Coester, Tim Heise, et al.
Clinical Therapeutics|October 4, 2016
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 DiabetesTim Heise, Jens Jordan, Christoph Wanner, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic studyRiccardo C Bonadonna, Tim Heise, Christophe Arbet-Engels, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Type 2 diabetes phenotype and progression is significantly different if diagnosed before versus after 65 years of ageHubert Kolb, Berthold Schneider, Lutz Heinemann, et al.
Journal of Diabetes|January 13, 2015
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of actionTim Heise, Stefan Korsatko, Leszek Nosek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 19, 2012
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitusThomas Rauch, Ulrike Graefe-Mody, Carolyn F Deacon, et al.
Clinical Therapeutics|September 27, 2016
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes MellitusTim Heise, Jens Jordan, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|May 22, 2020
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover studyTim Heise, Helle Linnebjerg, David Coutant, et al.
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover StudyJennifer Leohr, Mary Anne Dellva, David E Coutant, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Diabetes Care|July 15, 2016
Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose ControlSusanne Famulla, Ulrike Hövelmann, Annelie Fischer, et al.
Diabetes, Obesity & Metabolism|January 26, 2018
Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanismEric Zijlstra, Hans-Veit Coester, Tim Heise, et al.
Clinical Therapeutics|October 4, 2016
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 DiabetesTim Heise, Jens Jordan, Christoph Wanner, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic studyRiccardo C Bonadonna, Tim Heise, Christophe Arbet-Engels, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Type 2 diabetes phenotype and progression is significantly different if diagnosed before versus after 65 years of ageHubert Kolb, Berthold Schneider, Lutz Heinemann, et al.
Journal of Diabetes|January 13, 2015
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of actionTim Heise, Stefan Korsatko, Leszek Nosek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 19, 2012
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitusThomas Rauch, Ulrike Graefe-Mody, Carolyn F Deacon, et al.
Clinical Therapeutics|September 27, 2016
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes MellitusTim Heise, Jens Jordan, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|May 22, 2020
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover studyTim Heise, Helle Linnebjerg, David Coutant, et al.
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover StudyJennifer Leohr, Mary Anne Dellva, David E Coutant, et al.
Pageof 15